XML 38 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Apr. 04, 2025
Segment Reporting [Abstract]  
Schedule of Segment and Consolidated Net Income, Including Significant Segment Expenses
The segment and consolidated net income, including significant segment expenses were as follows (in thousands):
 Three Months Ended March 31,
 20252024
Revenues$555,447 $425,226 
Less:
Cost of goods sold
19,172 21,256 
Drug discovery
18,253 22,490 
Development
153,217 172,887 
Selling, general, and administrative
120,775 98,763 
Other segment items(1)
57,416 80,457 
Interest income
(19,076)(19,894)
Provision for income taxes
46,074 11,950 
Segment and consolidated net income$159,616 $37,317 
_________________
(1) Other segment items include stock-based compensation, restructuring expenses, other research and development expenses including the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements, and other expenses, net.